Open Access

Arginine methyltransferase inhibitor‑1 inhibits sarcoma viability in vitro and in vivo

  • Authors:
    • Baolai Zhang
    • Xue Chen
    • Suyin Ge
    • Caili Peng
    • Su Zhang
    • Xu Chen
    • Tao Liu
    • Wenkai Zhang
  • View Affiliations

  • Published online on: June 8, 2018     https://doi.org/10.3892/ol.2018.8929
  • Pages: 2161-2166
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Protein arginine methyltransferases (PRMTs) are a class of epigenetic modified enzymes that are overexpressed in a various types of cancer and serve pivotal functions in malignant transformation. Arginine methyltransferase inhibitor‑1 (AMI‑1) is a symmetrical sulfonated urea that inhibits the activity of type I PRMT in vitro. However, previous studies demonstrated that AMI‑1 may also inhibit the activity of type II PRMT5 in vitro. To the best of our knowledge, the present study provides the first evidence that AMI‑1 may significantly inhibit the viability of mouse sarcoma 180 (S180) and human osteosarcoma U2OS cells. Additionally, the results demonstrated that AMI‑1 downregulated the activities of PRMT5, the symmetric dimethylation of histone 4 and histone 3 (a PRMT5‑specific epigenetic mark) in a mouse xenograft model of S180 and induced apoptosis in S180 cells. Taken together, the results suggest that AMI‑1 may exhibit antitumor effects against sarcoma cells by targeting PRMT5.
View Figures
View References

Related Articles

Journal Cover

August-2018
Volume 16 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang B, Chen X, Ge S, Peng C, Zhang S, Chen X, Liu T and Zhang W: Arginine methyltransferase inhibitor‑1 inhibits sarcoma viability in vitro and in vivo. Oncol Lett 16: 2161-2166, 2018
APA
Zhang, B., Chen, X., Ge, S., Peng, C., Zhang, S., Chen, X. ... Zhang, W. (2018). Arginine methyltransferase inhibitor‑1 inhibits sarcoma viability in vitro and in vivo. Oncology Letters, 16, 2161-2166. https://doi.org/10.3892/ol.2018.8929
MLA
Zhang, B., Chen, X., Ge, S., Peng, C., Zhang, S., Chen, X., Liu, T., Zhang, W."Arginine methyltransferase inhibitor‑1 inhibits sarcoma viability in vitro and in vivo". Oncology Letters 16.2 (2018): 2161-2166.
Chicago
Zhang, B., Chen, X., Ge, S., Peng, C., Zhang, S., Chen, X., Liu, T., Zhang, W."Arginine methyltransferase inhibitor‑1 inhibits sarcoma viability in vitro and in vivo". Oncology Letters 16, no. 2 (2018): 2161-2166. https://doi.org/10.3892/ol.2018.8929